340B rebates, trade probes, and $6B in pharma deals
Supply Chain Pulse — 2026-04-29
HRSA is pushing forward with a 340B rebate pilot despite fierce provider opposition, while healthcare supply chain groups are weighing in on a Section 301 trade investigation that could reshape medical device sourcing from China. Meanwhile, $6 billion in pharma consolidation this week signals continued market reshuffling that will impact drug pricing and availability. The convergence of regulatory pressure, trade policy, and industry consolidation creates a perfect storm of supply chain uncertainty—time to stress-test your vendor diversification strategy.
Quick Hits
- A single word in 340B litigation could reshape the entire drug pricing program's future (Modern Healthcare)
- Mid-size PBMs warn Labor Department transparency rules would create costly compliance burdens (Modern Healthcare)
- Iran conflict dampens services and manufacturing growth, raising inflation concerns (Supply Chain Dive)
- Hospitals leverage command centers to streamline operations and improve care delivery (Modern Healthcare)
HRSA wants a 340B rebate pilot. Here's what the industry thinks
HRSA is moving ahead with a controversial 340B rebate pilot program despite strong provider pushback, while drugmakers argue rebates are the only way to restore program accountability. For supply chain leaders, this could fundamentally alter drug procurement economics at covered entities and create new administrative burdens around rebate tracking and compliance.
HSCA weighs in on Section 301 trade investigation targeting manufacturing overcapacity
The Healthcare Supply Chain Association has submitted formal comments on USTR's investigation into structural excess capacity in manufacturing, particularly regarding China. This probe could result in new tariffs or trade restrictions on medical devices and supplies, forcing procurement teams to evaluate supply chain diversification and cost modeling for alternative sourcing strategies.
Source: Healthcare Supply Chain Association
BioMarin completes $4.8B Amicus acquisition, adding rare disease pipeline
BioMarin has closed its acquisition of Amicus Therapeutics, bringing Galafold for Fabry disease and Pombiliti for Pompe disease into its portfolio. Supply chain teams should expect potential sourcing changes and supply continuity assessments for these specialized therapies, particularly as integration efforts may temporarily disrupt distribution channels.
Source: Pharmaceutical Business Review
Thermo Fisher divests $1B microbiology business to focus elsewhere
Thermo Fisher is selling its microbiology testing division to private equity firm Astorg for $1 billion, signaling a strategic retreat from in-vitro diagnostics. Lab procurement teams using Thermo Fisher micro products should prepare for potential vendor transitions and evaluate alternative suppliers for critical testing platforms.
Source: Medical Device Network
PBMs double down on private label biosimilars to boost margins
Healthcare conglomerates with PBM arms are increasingly favoring biosimilars manufactured by their overseas subsidiaries over independent alternatives. This vertical integration trend could limit formulary access for competing biosimilars and concentrate supply chains, requiring pharmacy leaders to monitor coverage decisions more closely.
Hospital M&A rebounds to pre-pandemic levels with 22 Q1 deals
Hospital transaction activity surged in Q1 2026 with 22 proposed deals, matching 2019 levels driven by Medicaid reimbursement cuts and expiring tax provisions. Supply chain leaders should prepare for integration challenges, vendor rationalization, and potential contract renegotiations as health systems consolidate purchasing power.
Hospital bankruptcies rise despite overall healthcare Chapter 11 decline
While total healthcare bankruptcies fell in 2025, hospital failures increased, with some facilities emerging from Chapter 11 only to fail again within months. Supply chain teams should enhance financial monitoring of hospital customers and consider credit insurance for high-risk accounts to avoid bad debt exposure.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe